Daniel R. Principe

Northwestern University — United States

Medicine · Health Sciences

30h-index3.1kcitations218works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(94), Pancreatic and Hepatic Oncology Research(87), Genetic factors in colorectal cancer(42), Cancer Cells and Metastasis(34), Colorectal Cancer Treatments and Studies(25)

Publications218 total

Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition
Molecular Cancer Therapeutics·2026
Effect of ROCK2 signaling on resistance to KRAS inhibitors in pancreatic cancer.
Journal of Clinical Oncology·2026
Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in <i>KRAS-STK11</i> NSCLC.
Journal of Clinical Oncology·2025
Resistance to the KRAS <sup>G12D</sup> Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition
2025Open Access
Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst <i>KRAS</i> mutational variants in non-small cell lung cancer
Cancer Research·2025
Figure S8 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S2 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S1 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S7 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S5 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Supplemental Figure Legends from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S4 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S3 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S6 from Loss of &lt;i&gt;STK11&lt;/i&gt; Suppresses Lipid Metabolism and Attenuates &lt;i&gt;KRAS&lt;/i&gt;-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
2025Open Access
Figure S2 from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024Open Access
Figure S5 from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024Open Access
Figure S7 from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024Open Access
Figure S3 from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024Open Access
Figure S1 from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024Open Access
Data from Targeting BCL2 with Venetoclax Enhances the Efficacy of the &lt;i&gt;KRAS&lt;/i&gt;&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor MRTX1133 in Pancreatic Cancer
2024· 1 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Hidayatullah G. Munshi(23), Paul J. Grippo(22), Ajay Rana(18), Sandeep Kumar(10), Brian DeCant(7), Navin Viswakarma(7), Patrick W. Underwood(6), Andrew M. Diaz(6), Lawrence B. Schook(6), Thao D. Pham(6), José G. Treviño(5), Barbara Jung(5), Kyle M. Schachtschneider(5), Matthew J. Dorman(5), Carolina Torres(5), Ronald McKinney(5), Suneel D. Kamath(5), Basabi Rana(5), Emman Mascariñas(4), Rosa F. Hwang(4)